Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 20, 2026, 7:30 AM ET
Zevra Therapeutics (ZVRA) will report third quarter 2026 financial results on Tuesday, November 3, 2026, after market close, with a conference call at 4:30 p.m. ET that day.
Nasdaq: $ZVRAMIPLYFFA / NPCEuropean re-examinationCommercial concentration
ZVRA Stock Hub: Zevra Therapeutics News, MIPLYFFA and European Review
MIPLYFFA growth must sustain cash generation while Europe follows its own review. Third-quarter results are scheduled for November 3. June cash and investments were $260.179M with positive H1 operating cash flow. The October 30 regular-session close was $10.28 (-0.77% versus October 29).
Full research report · PDF
Zevra Therapeutics ($ZVRA), research as of October 24, 2026
13 pages covering MIPLYFFA commercial growth, operating cash generation, European re-examination, NPC evidence limits, celiprolol, debt repayment and potential dilution. This is a dated research snapshot; the hub follows later developments. For personal use only: redistribution prohibited.
Next scheduled financial checkpoint
November 3, 2026 · after-close results; call at 4:30 p.m. ET
Zevra announced its third-quarter results date on October 20. MIPLYFFA sales, paid access and cash generation can be assessed separately from European regulatory review. Primary source
European re-examination follows the negative July opinion; the company’s Q4 timing expectation is not a promised decision or approval. H2 celiprolol dialogue likewise does not establish a fixed outcome.
ZVRA stock at a glance
Close · October 30, 2026
$10.28
Regular session; -0.77% versus $10.3600 on October 29.
Cash + investments · June 30
$260.179M
Includes $38.609M noncurrent investments; not all cash equivalents.
Q2 2026 net revenue
$39.663M
Company-reported quarter ended June 30.
Q2 MIPLYFFA net sales
$30.2M
Dominant commercial franchise.
H1 operating cash flow
+$23.174M
Generation, not cash burn.
H1 monthly operating average
+$3.86M
Calculated six-month cash generation divided by six.
Common shares · July 31
59.384M
Rounded quarterly-report cover count.
Term loan · June 30
$0
Loan repaid March 12, 2026.
Where Zevra Therapeutics stands now
Zevra is a commercial rare-disease company with MIPLYFFA as the dominant franchise. Q2 net revenue was $39.663M, including $30.2M from MIPLYFFA. H1 operating cash generation and the March term-loan repayment improve the dated financial base, while European review remains separate from U.S. approval. Primary source · Primary source
U.S. approval and commercial sales do not establish a favorable European re-examination. Product concentration, reimbursement, access, safety and pipeline execution remain material. Matched real-world subgroups complement controlled evidence but do not replace it.
The constructive case
Growing commercial sales, positive historical operating cash flow and repaid debt provide an operating base for access expansion and development.
The cautious case
Dependence on one franchise and uncertain European review can limit the operating opportunity. Enrollment forms, access requests and potential geographic markets are not all recognized revenue.
Latest Zevra Therapeutics news
October 20, 2026
Third-quarter 2026 results on November 3
On October 20, 2026 Zevra Therapeutics said it will report third-quarter 2026 financial results after the market close on Tuesday, November 3, 2026, followed by a conference call and audio webcast at 4:30 p.m. ET; a replay will be available for 90 days on the investor relations site. The announcement contains no financial figures.
September 14–17, 2026
European re-examination starts after the negative opinion
EMA’s September meeting highlights record the start of re-examination for Meplyffa after the negative July opinion. Re-examination is an ongoing assessment, not a favorable recommendation or marketing authorization.
September 2, 2026
September investor-conference participation announced
Zevra announced presentations at Cantor on September 9, Morgan Stanley on September 14 and H.C. Wainwright on September 15. These investor events have passed and do not themselves establish a regulatory outcome.
August 25, 2026
long-term NPC observations
The SSIEM announcement describes US and German real-world experience. The matched US year-four subgroup comprised 20 participants; those data complement controlled evidence without replacing it.
August 21, 2026
employee option awards
Zevra announced options covering 92,200 shares for four new employees, vesting over four years. These are potential future shares, not an immediate common-stock issuance.
August 5, 2026
operating growth and liquidity
Q2 net revenue reached $39.663M, including $30.2M from MIPLYFFA. June cash and investments were $260.179M, with the term loan already repaid.
ZVRA stock catalysts: MIPLYFFA results and European re-examination
- November 3, 2026 · 4:30 p.m. ET — Third-quarter financial-results call after the close. Scheduled company event
- Q4 2026 company expectation — European opinion following requested re-examination. Regulatory process; no guaranteed date
- H2 2026 company plan — FDA dialogue on the celiprolol development path. Development interaction, not approval
MIPLYFFA sales and the distinction between enrollment and paid access
The global expanded-access program had 132 enrolled patients at June 30, 2026. Separately, the commercial MIPLYFFA program had received 161 cumulative enrollment forms by December 31, 2025. Those forms initiate reimbursement review and are not a count of paid patients; the EAP population is another distinct measure. Zevra Q2 2026 earnings release (SEC Exhibit 99.1). Zevra 2025 Form 10-K.
Zevra received 14 MIPLYFFA prescription enrollment forms during the second quarter of 2026, bringing the cumulative total since launch to 184 at June 30. The company also reported coverage of 69% of covered lives. These are useful access indicators, but neither is a direct count of continuously paying patients. An enrollment form starts the specialty-pharmacy benefits process; it is not proof that a patient has completed a paid dispense or remained on therapy for the full quarter. Source Source
European re-examination and the limits of the NPC evidence
EMA’s July opinion recommended refusal. The EPAR records the request for re-examination; that request is a process step, not a favorable final recommendation. Zevra’s expected Q4 timing remains management guidance. Primary source
The long-term matched U.S. year-four subgroup comprised 20 participants. Real-world follow-up can add context while selection, matching and the small subgroup limit causal interpretation.
Merlintrader Health Score · $ZVRA
3.50out of 5
Assessed October 4, 2026. Weighted calculation: 4.5×30% + 2.5×30% + 3.5×20% + 3.0×10% + 4.0×10% = 3.50. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Commercial concentration in MIPLYFFA remains substantial.
- European re-examination is not a completed approval.
- Access and enrollment measures differ from recognized paid sales.
- Matched real-world subgroups have limitations distinct from randomized evidence.
- Positive historical operating cash flow does not guarantee future cash generation.
ZVRA Stock FAQ: Zevra Therapeutics Questions Answered
Is MIPLYFFA already approved in Europe?
The US FDA approved MIPLYFFA on September 20, 2024. Europe is a separate process: the July 23, 2026 negative opinion was followed by requested re-examination, listed in EMA’s September meeting highlights. It is not a completed European approval. Source Source Source
Does Zevra have a monthly cash burn?
The first half of 2026 generated $23.174M of operating cash, a calculated average of approximately $3.86M monthly. A positive-burn runway formula is not meaningful for that period; future cash generation can change. Source
Is the entire $260.179M balance cash?
No. At June 30, 2026 it comprised $145.321M cash and equivalents, $76.249M current investments and $38.609M noncurrent investments. The aggregate includes securities maturing beyond one year. Source
Primary sources
- October 20, 2026 — Third-quarter 2026 results on November 3
- September 14–17, 2026 — European re-examination starts after the negative opinion
- September 2, 2026 — September investor-conference participation announced
- August 25, 2026 — long-term NPC observations
- August 21, 2026 — employee option awards
- August 5, 2026 — operating growth and liquidity
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ZVRA or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Zevra is a commercial biotechnology company with positive operating cash generation in the reported first half. That does not remove product concentration, reimbursement, access, safety or development risks. European review and pipeline outcomes remain uncertain, and future financing needs depend on spending and operating performance. Historical cash generation does not guarantee future returns. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
